Holen Sie sich die Stockscreener-App
25.80
8.68%
2.06
Handel nachbörslich:
26.42
0.62
+2.40%
Schlusskurs vom Vortag:
$23.74
Offen:
$24.35
24-Stunden-Volumen:
373.78K
Relative Volume:
0.84
Marktkapitalisierung:
$92.57M
Einnahmen:
$7.97M
Nettoeinkommen (Verlust:
$-75.74M
KGV:
-1.0624
EPS:
-24.2853
Netto-Cashflow:
$-85.33M
1W Leistung:
-15.22%
1M Leistung:
-35.24%
6M Leistung:
+98.46%
1J Leistung:
+49.57%
1-Tages-Spanne:
$24.10
$27.61
1-Wochen-Bereich:
$21.65
$30.02
52-Wochen-Spanne:
$6.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Firmenname
Aligos Therapeutics Inc
Sektor
Branche
Telefon
(800) 466-6059
Adresse
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Vergleichen Sie ALGS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
25.80 | 92.57M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-01-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-01-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-09 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-10 | Eingeleitet | Jefferies | Buy |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Aligos Therapeutics Inc Aktie (ALGS) Neueste Nachrichten
(ALGS) On The My Stocks Page - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 30.7% in January - MarketBeat
Drive Wealth Management LLC Takes $916,000 Position in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - MarketBeat
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) market cap surged US$16m last week, retail investors who have a lot riding on the company were rewarded - Simply Wall St
When the Price of (ALGS) Talks, People Listen - Stock Traders Daily
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Reviewing Aligos Therapeutics (NASDAQ:ALGS) & Genetic Technologies (NASDAQ:GENE) - Defense World
4Q24 Wrap: They all fall down - BioCentury
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Update - MarketBeat
Here’s Why Aligos Therapeutics, Inc. (ALGS) Is Skyrocketing - MSN
How Is The Market Feeling About Aligos Therapeutics? - Benzinga
Why These 24 Stocks Are Skyrocketing - Insider Monkey
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Aligos Therapeutics (NASDAQ:ALGS) & Artiva Biotherapeutics (NASDAQ:ARTV) Head to Head Contrast - Defense World
ALGS stock soars to 52-week high, hits $44.5 amid robust gains - Investing.com Nigeria
(ALGS) Long Term Investment Analysis - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest - MarketBeat
Aligos Therapeutics stock soars to 52-week high of $42.99 By Investing.com - Investing.com Nigeria
Aligos Therapeutics stock soars to 52-week high of $42.99 - Investing.com India
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last week - Yahoo Finance
Charles Schwab Investment Management Inc. Lowers Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Charles Schwab Investment Management Inc. Sells 19,403 Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) vs. Aligos Therapeutics (NASDAQ:ALGS) Head to Head Analysis - Defense World
Aligos Therapeutics stock soars to 52-week high of $35.47 - Investing.com
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics Awards Key Talent Retention Stock Options Under 2024 Inducement Plan | ALGS Stock News - StockTitan
Aligos Therapeutics: Promising Pipeline With Cash And Dilution Risks (NASDAQ:ALGS) - Seeking Alpha
How To Trade (ALGS) - Stock Traders Daily
Aligos stock hits 52-week high at $30.01 amid robust gains - Investing.com India
Baker BROS. Advisors LP Decreases Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - MarketBeat
Aligos Therapeutics Inc (ALGS) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Growth in Short Interest - Defense World
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 140.3% in November - MarketBeat
Can Aligos Therapeutics (NASDAQ:ALGS) Afford To Invest In Growth? - Simply Wall St
Aligos Therapeutics to Present at Investor Conferences in December - The Manila Times
Aligos Therapeutics to Present at Two Major Healthcare Investor Conferences in December | ALGS Stock News - StockTitan
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
Aligos Therapeutics files $400M mixed securities shelf - MSN
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 - The Manila Times
Aligos Reports 100% HBV Suppression Success, Strong MASH Treatment Results in Clinical Trials | ALGS Stock News - StockTitan
EcoR1 Capital, LLC Increases Stake in Aligos Therapeutics Inc - GuruFocus.com
ARMISTICE CAPITAL, LLC Expands Stake in Aligos Therapeutics Inc - GuruFocus.com
Compass Therapeutics Inc (CMPX) Quarterly 10-Q Report - Quartz
Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Expands By 46.5% - MarketBeat
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Finanzdaten der Aligos Therapeutics Inc-Aktie (ALGS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):